Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities-Reference-Cited by-同舟云学术

Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities

Published:2017-05-16 Issue:6 Volume:37 Page:1461-1491
ISSN:0198-6325
Container-title:Medicinal Research Reviews
language:en
Short-container-title:Med. Res. Rev.

Author:

Rajawat Jyotika¹,Shukla Nidhi¹,Mishra Durga Prasad¹^ORCID

Affiliation:

1. Cell Death Research Laboratory, Endocrinology Division; CSIR-Central Drug Research Institute; B.S. 10/1, Sector-10, Jankipuram Extension Lucknow Uttar Pradesh 226031 India

Funder

Department of Biotechnology, Govt of India

Publisher

Wiley

Subject

Drug Discovery,Pharmacology,Molecular Medicine

Reference158 articles.

1. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics;He;Acta Pharmacol Sin,2010

2. Poly(ADP-ribose) polymerase: A molecular nick-sensor;Murcia;Trends Biochem Sci,1994

3. PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications;Drew;Drug Resist Updat,2009

4. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase;Ame;J Biol Chem,1999

5. The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction;Langelier;J Biol Chem,1992

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells;International Journal of Molecular Sciences;2024-08-23

2. Transcriptional regulation mechanism of PARP1 and its application in disease treatment;Epigenetics & Chromatin;2024-08-08

3. Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship;European Journal of Medicinal Chemistry;2024-08

4. Cytotoxic Activity and Molecular Docking Studies of the Fraction Containing Ergosta-14,22-dien-3-ol (3β, 5α, and 22E) from Dysidea avara Sponges;Jundishapur Journal of Natural Pharmaceutical Products;2024-06-16

5. Loss of cytidine deaminase expression as a potential attempt to counteract the process of carcinogenesis by reducing basal PARP-1 activity and increasing tau levels;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-06